Genomic Health EVP Steven Shak Unloads 13,348 Shares (GHDX)
Genomic Health (NASDAQ:GHDX) EVP Steven Shak unloaded 13,348 shares of the stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $27.36, for a total transaction of $365,201.28. Following the completion of the sale, the executive vice president now directly owns 312,298 shares in the company, valued at approximately $8,544,473. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of Genomic Health (NASDAQ:GHDX) traded up 0.22% during mid-day trading on Friday, hitting $27.76. 335,162 shares of the company’s stock traded hands. Genomic Health has a one year low of $23.90 and a one year high of $37.24. The stock’s 50-day moving average is $26.72 and its 200-day moving average is $27.06. The company’s market cap is $875.2 million.
Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.15) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.26) by $0.11. The company had revenue of $70.50 million for the quarter, compared to the consensus estimate of $69.04 million. During the same quarter in the prior year, the company posted ($0.10) earnings per share. The company’s quarterly revenue was up 10.7% on a year-over-year basis. On average, analysts predict that Genomic Health will post $-0.80 earnings per share for the current fiscal year.
Separately, analysts at Canaccord Genuity reiterated a “hold” rating on shares of Genomic Health in a research note on Monday, August 11th. They now have a $27.00 price target on the stock, down previously from $30.00. Four analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $27.50.
Genomic Health, Inc (NASDAQ:GHDX) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.